Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
11.41
+0.96 (+9.19%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
March 15, 2024
Via
AB Newswire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
March 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
March 14, 2024
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
February 16, 2024
The TDR Three Key Takeaways:
Via
Benzinga
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
March 13, 2024
Via
Benzinga
Exposures
Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
March 13, 2024
Via
Investor Brand Network
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
March 13, 2024
From
Cybin Inc.
Via
Business Wire
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
March 12, 2024
From
Cybin Inc.
Via
Business Wire
3 High-Potential Penny Stocks to Turn $1000 into $1 million
March 10, 2024
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices.
Via
InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
February 27, 2024
Via
Investor Brand Network
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Cybin Inc.
Via
Business Wire
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures Two New JP Patents, Further Broadening IP Portfolio in Key Markets
February 07, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
February 07, 2024
From
Cybin Inc.
Via
Business Wire
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety
January 23, 2024
Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment.
Via
Benzinga
Exposures
Product Safety
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives FDA Clearance to Begin CYB004 Study for Generalized Anxiety Disorder
January 23, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
January 23, 2024
From
Cybin Inc.
Via
Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
January 10, 2024
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...
Via
Benzinga
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
January 09, 2024
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Topline Data from Phase 1 CYB004 and SPL028 Studies
January 08, 2024
Via
Investor Brand Network
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
January 08, 2024
From
Cybin Inc.
Via
Business Wire
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Eyes Enormous Opportunities Across Its Clinical Development Programs
January 04, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.